



## Acute renal failure in patients with COVID-19: A literature review

  <https://doi.org/10.56238/emerrelcovid19-063>

### Milena Maria Felipe Girão

Academic of the medical course Federal University of Cariri

### Harnowd Felipe Nogueira de Carvalho

Academic of the medical course Federal University of Cariri

### Tatiane Ribeiro de Moraes

Academic of the medical course Federal University of Cariri

### Lucas Pereira Albuquerque

Academic of the medical course Federal University of Cariri

### Metton Ribeiro Lopes e Silva

Graduated in Biomedicine specialist in Exfoliative Cytology and Oncohematology Laboratory Vicente Lemos/Crato-CE

### Claudio Gleidiston Lima da Silva

Physician, Post-Doctorate from the ABC-SP Medical School (2016), in the area of concentration Collective Health  
Professor at the Federal University of Cariri – UFCA

### Maria do Socorro Vieira dos Santos

Veterinary Physician, Post-Doctorate from the Medical School of ABC-SP (2016), in the area of concentration Collective Health  
Professor at the Federal University of Cariri – UFCA

### ABSTRACT

Introduction: Acute kidney injury (AKI) is a serious complication of the disease caused by the new

SARS-CoV-2 and derives from numerous factors such as direct damage to the renal structures by the virus, the use of nephrotoxic drugs and the cytokine storm in response to the etiologic agent. Objective: In view of the relevance of AKI in the clinical outcome, the present study aimed to list the main aspects of the development of this complication in patients with COVID-19. Methods: A literature review was performed using the Virtual Health Library and Pubmed databases, adopting the descriptors “acute kidney injury” and “coronavirus 19”. Results: 635 articles related to the topic were found, of which, after applying the inclusion and exclusion criteria, 23 studies were selected to integrate this review. The articles included were classified as retrospective cohorts and their samples were composed of individuals from Europe, Asia and the Americas. Discussion: Proteinuria, hematuria, leukocyturia and AKI were common clinical findings of renal impairment. AKI is a modifiable and multifactorial risk factor, uncommon in mild and moderate cases and common in severe cases. Age greater than 65 years, presence of comorbidities and laboratory tests with relevant alterations are important risk factors involved in AKI. Patients with stage 3 AKI required renal replacement therapy and were associated with an increased risk of developing chronic kidney disease. Conclusion: In patients with COVID-19 admitted to the ICU, a careful analysis of the clinical history and strict monitoring of laboratory tests are necessary to prevent the development of AKI.

**Keywords:** COVID-19, Risk factors, Kidney damage.

## 1 INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic began in 2020 and has represented, in recent years, a leading role in several studies to better understand the pathophysiological repercussions on the human body<sup>1</sup>. This pathology manifests clinically in an asymptomatic or symptomatic form, with mild or severe respiratory involvement, febrile syndrome, shock, electrolyte disturbances and acute renal failure (ARF) as a result of multiple organ failure<sup>2</sup>.

Acute kidney injury (AKI), recognized as a morbidity and mortality factor in hospitalized severe COVID-19 patients, presents pathogenesis related to multiple factors, such as the direct cytopathic effect on podocytes and tubules and accessory damage as a result of the use of nephrotoxic drug therapy<sup>3</sup>. Moreover, the systemic inflammatory response generates a storm of cytokines that activate the complement system and cause endothelial dysfunction<sup>4</sup>.

Common clinical presentations as a result of renal impairment revolve around hematuria and proteinuria. Studies have shown that more than 40% of hospitalized patients manifested the aforementioned symptoms<sup>5</sup>. Moreover, the microscopic evaluation of the urine of these patients pointed to the presence of acute tubular lesion with granulous and cloudy brown casts, in addition to leukocyturia<sup>6</sup>.

AKI, as a result of COVID-19, is a disorder associated with a worse clinical outcome in patients with severe SARS-CoV-2<sup>7</sup>. In this context, the present study aimed to analyze the factors involved in the development of acute kidney disease in patients with severe COVID-19 disease.

## 2 METHODS

This is a literature review in the Public Medline (PUBMED) and Virtual Health Library (VHL) databases, from 2020 to 2022. The following descriptors were used: "acute kidney injury" and "coronavirus 19", in addition to the Boolean operators AND and OR.

The inclusion criteria were original articles published in English, Portuguese and Spanish, full articles and available in full. The exclusion criteria were articles that do not dialogue with the proposed theme, works written in languages other than those mentioned above, literature and/or systematic reviews, case reports and letter to the editor.


The selection of articles was performed by two independent evaluators and, in case of disagreements, a third examiner was called for the final consensus. The results were arranged in a spreadsheet, including year of publication, authors, databases and journals.

## 3 RESULTS

The search in the databases identified 635 publications. After the analysis of the title and abstract, only 69 articles had the full text evaluated and the other 566 were excluded. In the end, 23 articles were included and 46 did not meet the eligibility criteria because they did not dialogue with the objective of this review.

Figure 1 presents the flowchart with the inclusion and exclusion criteria specified for the selection of studies according to the PRISMA (*Preferred Reporting Items for Systematic Reviews and Meta-Analyses*) model (PAGE *et al.*, 2021).

Figure 1. PRISMA flowchart adapted from the selection of literature review articles (PAGE *et al.* , 2021).



All included articles were classified according to the type of study, as retrospective cohorts, published between 2020 (21.73%) and 2021 (78.27%). The study samples included individuals from countries on three continents: Europe, Asia and America. China (5), the United Kingdom (3), the United States (2), Turkey (2) and Brazil (2) were the countries that most repeated themselves in the cohorts included in the qualitative synthesis. No studies on AKI in COVID-19 patients in countries in Africa and Oceania have been identified. Information on the location of the studies and the main results evidenced in the publications are shown in Table 1.

Most studies have shown the number of individuals with COVID-19 who have progressed to AKI. Thus, the highest incidence of AKI in patients infected with SARS-CoV-2 was 71.22%, identified in a Brazilian cohort whose mean age was 60 years<sup>1</sup>. In parallel, the lowest incidence (1.2%) was reported in a publication that evaluated AKI in children diagnosed with COVID-19 in a Chinese hospital<sup>19</sup>.

Table 1. Characteristics of the articles included in the qualitative synthesis of the literature review.

Author and Year	Sample Country	Sample	Main Results
Jewell <i>et al.</i> , 2021	United Kingdom	1248 adult patients with COVID-19 were enrolled at <i>King's College Hospital</i> in London.	The presence of chronic kidney disease (CKD) prior to admission increased the risk of developing AKI in hospitalized patients with COVID-19. Hypertension and diabetes were more frequent among patients with AKI than those without AKI. The use of hospital diuretics was associated with a risk of AKI. Black ethnicity was an independent predictor of AKI <sup>2</sup> .
Chen <i>et al.</i> , 2021	China	823 COVID-19 patients who were treated in Wuhan hospitals.	Hypophosphatemia was an independent risk factor for the development of AKI in hospitalized patients with COVID-19. Patients with AKI were also more likely to die than patients without AKI <sup>5</sup> .
Naser <i>et al.</i> , 2021	Bahrain	353 patients admitted to <i>Bahrain Defence Force (BDF)</i> hospital from April 2020 to October 2020.	Diabetes, hypertension, CKD and cardiovascular disease were higher in patients with AKI. Individuals who developed AKI had elevated inflammatory, cardiac or hypercoagulable serum markers and lymphopenia <sup>9</sup> .
Li <i>et al.</i> , 2021	China	223 patients, 52 patients from <i>Wuhan University's Zhaongnan Hospital</i> , 70 from <i>Leishenshan Hospital</i> , and 101 patients from <i>Jiangjunshan Hospital</i> .	COVID-19 patients with AKI had a higher rate of pre-existing hypertension and cytokine storm compared to patients without AKI. More than half of the patients who received invasive mechanical ventilation developed AKI. Of the COVID-19 patients with ARF, 57.1% were susceptible to bacterial infection <sup>10</sup> .
Alfano <i>et al.</i> , 2021	Italy	307 patients admitted to the <i>University Hospital of Modena</i> with SARS-CoV-2 infection.	CKD, evaluation of non-renal sequential organ failure (SOFA), male gender, age over 65 years and glomerular filtration rate (GFR) lower than 45 ml/min were statistically significant risk factors for AKI <sup>11</sup> .
Chopra <i>et al.</i> , 2021	India	105 patients admitted no department of pediatrics from a tertiary care	The presence of sepsis, vasopressor support, hemodynamic instability,

		university hospital in New Delhi.	shock in the time of presentation, need for mechanical ventilation, and nephrotic syndrome were relevant risk factors for the development of AKI in children infected with SARS-CoV-212.
Charoenngam, <i>et al.</i> , 2021	United States	1424 COVID-19 patients who were hospitalized at <i>Boston Medical Center (BMC)</i> .	Black patients with COVID-19 were approximately 2.2 times more likely to develop in-hospital AKI and had higher levels of inflammatory markers compared to white patients with AKI13.
Caceres <i>and al.</i> , 2021	United States	52 patients admitted to <i>Henry Ford Hospital in Detroit, Michigan</i> , with a clinical diagnosis of COVID-19.	A higher viral load of SARS-CoV-2 in urinary sediments of patients with COVID-19 correlated with increased incidence of AKI and mortality14.
Almeida <i>et al.</i> , 2021	Brazil	278 patients adults Boarding schools.com COVID-19 at the Hospital of the Federal University of São Paulo with COVID-19.	Hematological and inflammatory markers, hypertension, mechanical ventilation, and therapy with vasopressors have been associated with AKI in patients with severe COVID-19. Combined treatment with hydroxychloroquine and azithromycin was associated with renal dysfunction in these patients1.
Mohaved <i>et al.</i> , 2021	Iran	854 adult patients admitted with COVID-19 at <i>Baharloo Hospital in Tehran</i> were included.	The incidence of AKI in patients with COVID-19 was higher in patients receiving antibiotics against co-infections, in male patients, and in the elderly. The effects were greater in deaths and ICU admission, and AKI was associated with prolonged hospitalization15.
Xu <i>et al.</i> , 2021	Sweden	316 seniors with COVID-19 and 875 without COVID-19 were included, all of whom were admitted to two geriatric clinics in two hospitals in Stockholm.	The odds of developing AKI in elderly patients with COVID-19 were higher in those with reduced baseline kidney function and in patients with initial C-reactive protein (CRP) greater than 10 mg/L3.
Lowe <i>et al.</i> , 2021	United Kingdom	81 adult patients were admitted to the ICU of the <i>University Teaching</i>	The risk factors for the development of AKI were advanced age, diabetes <i>mellitus</i> and

		<i>Hospital</i> in Southampton diagnosed with COVID-19.	immunosuppression. AKI was associated with increased disease severity on admission, mechanical ventilation, elevated D-dimer and severe lymphopenia <sup>16</sup> .
This <i>et al.</i> , 2021	Singapore	707 COVID-19 patients admitted to the <i>National Center of Infectious Disease</i> .	Advanced age, congestive heart failure, initial use of iACE (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-converting enzyme blockers) or ARB (angiotensin-converting enzyme blockers) angiotensin), initial statin use, exposure to aminoglycoside and vancomycin, use of NSAIDs (nonsteroidal anti-inflammatory drugs) in the hospital, exposure to contrast testing, and hypoxia were associated with an increased risk of developing AKI in SARS-CoV-2 <sup>17</sup> infected patients.
Diebold <i>et al.</i> , 2021	Switzerland	188 patients adults Hospitalized No <i>University Hospital of Basel</i> , tested positive for COVID-19.	AKI in patients with COVID-19 occurs more in those in need of care and the severity of the condition correlates with the severity of the disease. Risk factors such as age, history of CKD, CRP levels and creatine kinase were identified as independent predictors of AKI <sup>16</sup> .
Costa <i>et al.</i> , 2021	Brazil	114 patients diagnosed with COVID-19 in the ICU of a private hospital in the ityo.	As independent predictors of the occurrence of AKI in patients with COVID-19, age and hypertension were identified <sup>7</sup> .
Pine <i>et al.</i> , 2021	Spain	237 patients who were admitted to the ICUs of the <i>Hospital Clínic of Barcelona</i> with a diagnosis of COVID-19 and AKI.	The prevalence of moderate/severe AKI in patients with COVID-19 admitted to the ICU is high and has a strong correlation with mortality and length of hospital stay <sup>18</sup> .
Wang <i>et al.</i> , 2021	China	238 COVID-19 cases admitted not Wuhan Children's Hospital.	Children critically ill with COVID-19 can develop AKI, especially after prodromal gastrointestinal symptoms. An inflammatory storm and complement-mediated injury may underlie the development of AKI in

			children with COVID-19.
Yan <i>et al.</i> , 2021	China	882 patients over 65 years of age hospitalized by COVID-19 were recruited at <i>Tongji Hospital</i> .	It has been established that the incidence of AKI in patients with COVID-19 increases with age, due to the decline in renal function with aging, and with the increase in the number of preexisting comorbidities <sup>20</sup> .
Hamilton <i>et al.</i> , 2020	United Kingdom	1032 adult patients were admitted to the <i>Manchester University Foundation Trust Hospitals</i> with clinical and/or virological diagnosis of COVID-19.	Independent risk factors related to the development of AKI in patients with COVID-19 were being male or black, having higher serum sodium and baseline CRP, as well as a previous diagnosis of kidney disease <sup>4</sup> .
Li <i>et al.</i> , 2020	China	107 patients Elderly hospitalized with COVID-19 were included.	AKI can be seen as an indicator of poor prognosis, revealing more severe and multi-organ dysfunction. Independent predictors of incident AKI in patients hospitalized for SARS-CoV-2 infection who developed AKI in the ICU were septic shock, invasive mechanical ventilation and the need for vasopressors <sup>21</sup> .
Trabulus <i>and to the.</i> , 2020	Turkey	336 COVID-19 patients admitted to the tertiary university hospital in Istanbul.	AKI was more common in patients with estimated glomerular filtration rate (eGFR) baseline less than 60 mL/min/1.73 m <sup>2</sup> . At admission, eGFR appears to be a prognostic marker for mortality in patients with COVID-19 <sup>22</sup> .
Oussalah <i>and al.</i> , 2020	France	149 patients with a confirmed diagnosis of COVID-19 and ACE inhibitor/ARB use data admitted to <i>the University Hospital of Nancy</i> .	The results corroborate the hypothesis of a deleterious effect of long-term therapy with iACE or ARB among patients with severe COVID-19 in relation to the risk of developing AKI <sup>23</sup> .

#### 4 DISCUSSIONS

Initial reports regarding the current COVID-19 pandemic suggested a limited respiratory condition with little involvement of several organs, however it was evident, with the progression of the disease, the involvement of extra-respiratory organs<sup>4</sup>. Proteinuria, hematuria, leukocyturia and AKI have been described as common clinical presentations of renal involvement<sup>6</sup>.

AKI in patients with COVID-19 is an important complication of the disease<sup>2</sup>, being listed as a modifiable risk factor for mortality in patients with COVID-19, especially in environments with limited resources<sup>12</sup>. In mild to moderate cases, AKI is not common and is determined by subclinical renal abnormalities, in contrast, it is common in critically ill patients with COVID-19, affecting approximately 20% to 40% of ICU patients<sup>1</sup>.

The etiological mechanism of AKI in patients with COVID-19 is multifactorial, including direct virus injury, cytokine storm syndrome, antiviral drugs and vasoconstrictors<sup>5</sup>. Other factors include the use of nephrotoxic agents, such as NSAIDs<sup>12</sup>, as well as hemodynamic and hypercoagulability changes<sup>9</sup>. One study demonstrated evidence based on immunodetection of the expression of two SARS-CoV-2 proteins, nucleocapsid and spike in kidney cells from COVID-19<sup>14</sup> biopsy samples. The virus also directly infects tubular epithelial cells and podocytes, causing significant structural damage<sup>16</sup>.

Cytokine storm and complement activation may play key roles in the pathogenesis of AKI in children with COVID-19, and subsequent dehydration with hypoperfusion of the kidneys increases the risk of developing AKI<sup>19</sup>. Secondary bacterial infections are also responsible for the cytokine storm, especially in individuals with decayed or compromised long-term immunity<sup>10</sup>. For the treatment of these opportunistic bacterial infections it is necessary to intervene with antibiotics, exposing the patient to nephrotoxic drugs such as vancomycin and amikacin<sup>12</sup> that can lead to renal lesions, such as acute tubular necrosis and acute interstitial nephritis, direct cytotoxicity of the proximal tubule. Therefore, appropriate dosing of antibiotics should be administered to COVID-19 patients and monitored frequently to prevent AKI<sup>15</sup>.

In a cohort study in the United Kingdom, the average age of patients with AKI and COVID-19 was 69 years, 58% were male and 59.1% white and 27.4% black<sup>2</sup>. Age over 65 years is a strong predictor for AKI<sup>11</sup>. In children, the median age was 6 years, with the majority (47.6%) in the group of 5 to 13 years<sup>12</sup>. Age 80 to 90 years was associated with higher odds of AKI in patients with COVID-19<sup>3</sup>. The study by Costa et al.<sup>7</sup> corroborated with age and gender profile, being mostly male (58.5%) and with a mean age of 66.5 years, also addresses that the mean body mass index (BMI) of the patients evaluated was 28 kg/m<sup>2</sup>.

Although the aforementioned cohort study in the United Kingdom points to a higher prevalence of AKI in COVID-19 in whites, the study by Charoenngam et al.<sup>13</sup> demonstrated that black individuals are more likely than whites to develop AKI. These differences can be explained by genetic particularities, socioeconomic status, access to care, diet, cultures, and other factors, as well as the interaction between them. Levels of inflammatory markers were higher in black patients, suggesting racial differences in the inflammatory burden of COVID-19<sup>13</sup>.

The main risk factors involved in AKI in patients with COVID-19 include long-term therapy with iACE and ARB<sup>23</sup>, use of statins before hospitalization, use of nephrotoxic drugs during hospitalization<sup>17</sup>, presence of comorbidities, glomerular filtration rate on admission<sup>22</sup>, as well as increased mean initial CRP value<sup>3</sup>. Critically ill patients with COVID-19 may be at increased risk of AKI due to hypoperfusion of the kidneys as a result of circulatory shock secondary to hypovolemia, sepsis, or cardiogenic shock due to underlying cardiovascular disease or new cardiac event<sup>17</sup>.

In addition, the laboratory tests that make up risk factors for AKI include thrombocytopenia, hypoalbuminemia, hypophosphatemia, in contrast to higher levels of lactate dehydrogenase (LDH), procalcitonin, CRP, urea and prothrombin time on admission<sup>5</sup>, as well as D-dimer, troponin I, ProBNP and ferritin. Thus, laboratory tests for serum albumin, hypercoagulability and markers of cardiac injury may be indicative of the development of AKI<sup>9</sup>. Children with AKI had leukocytosis and thrombocytopenia<sup>12</sup>, and also had anemia and thrombocytopenia<sup>19</sup>.

Regarding comorbidities, hypertension was the most common, followed by diabetes mellitus<sup>22</sup>. In addition, cardiovascular disease, chronic obstructive pulmonary disease (COPD), cerebrovascular disease<sup>21</sup>, previous diagnosis of kidney disease<sup>4</sup>, immunosuppression by any reason, including HIV, myelosuppression by hematological neoplasms and immunosuppressive therapy<sup>16</sup>. In the elderly, there is also a record of dementia<sup>3</sup>. Comorbidity in children is related to pneumonia, tuberculosis and hematological disorders/malignancy<sup>12</sup>. The presence of two or more comorbidities substantially increased the risk of developing AKI in patients with COVID-19<sup>9</sup>.

Among patients with COVID-19 AKI, stage 3 received renal replacement therapy (RRT). All surviving patients with stages 1 and 2 and 3 with RRT had complete recovery of baseline renal function<sup>16</sup>. Normally, in the stage 1 and 2 group of AKI there were no deaths<sup>7</sup>. Patients with AKI were more likely to be admitted to intensive care, ventilated, more likely to die<sup>4</sup>, as well as more likely to use vasopressors and had high levels of urea nitrogen in the blood and uric acid<sup>21</sup>. Sepsis, septic shock, acute respiratory distress syndrome (ARDS), myocardial injury and liver injury were commonly observed complications in patients with AKI<sup>20</sup>. AKI has been associated with an increased risk of chronic kidney disease (CKD) in individuals with previously normal renal function and acute venous thromboembolism<sup>2</sup>.

In the cohort study by Piñeiro et al.<sup>18</sup> The treatment protocol for COVID-19 includes antiviral therapy with lopinavir/ritonavir, hydroxychloroquine, and azithromycin. If patients presented clinical deterioration, biological therapy was recommended, which most often included tocilizumab, anakinra, and/or corticosteroids. Corticosteroid use was associated with a 13% reduction in the need for RRT. Favipiravir may be an appropriate therapeutic option in pediatric patients with SARS-CoV-2 with reduced GFR without the need for dose adjustment<sup>24</sup>.

## 5 CONCLUSION

Acute kidney injury (AKI) is a common finding of renal involvement related to SARS-CoV-2 infection, being more frequent in severe cases and an important predictor of clinical outcome, especially in patients with stage 3 AKI. Because it has a multifactorial pathogenic mechanism, it is extremely important to pay attention to the treatment used during the hospitalization period, adjusting the dose and carefully monitoring the patient submitted to nephrotoxic drugs, and it is essential to monitor the levels of substances that predict AKI in the blood.

A careful analysis of the patient's clinical history is necessary, considering that the risk factors include several comorbidities and findings in laboratory tests. The advanced age ( $\geq 65$  years) should be seen as a relevant variable for the development and outcome of the case. At the moment, ethnicity should not be listed as a predictor, since there are divergences in the existing literature, evidencing the need for further research on the subject. It is essential to emphasize that patients who survived 3rd stage AKI during the treatment of COVID-19 should have medical follow-up within 6 months of the outcome of the case, which is due to the high risk of developing chronic kidney disease.

## REFERENCES

- Almeida DC, Franco MDCP, Santos DRP, Santos MC, Maltoni IS, Mascotte F, et al. Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients. *PLoS One*. 2021;16(5):e0251048.
- Jewell PD, Bramham K, Galloway J, Post F, Norton S, Teo J, et al. COVID-19-related acute kidney injury; incidence, risk factors and outcomes in a large UK cohort. *BMC Nephrol*. 2021;22(1):359.
- Xu H, Garcia-Ptacek S, Annetorp M, Bruchfeld A, Cederholm T, Johnson P, et al. Acute kidney injury and mortality risk in older adults with COVID-19. *J Nephrol*. 2021;34(2):295-304.
- Hamilton P, Hanumapura P, Castelino L, Henney R, Parker K, Kumar M, et al. Characteristics and outcomes of hospitalised patients with acute kidney injury and COVID-19. *PLoS One*. 2020;15(11):e0241544.
- Chen Z, Gao C, Yu H, Lu L, Liu J, Chen W, et al. Hypophosphatemia is an independent risk factor for AKI among hospitalized patients with COVID-19 infection. *Ren Fail*. 2021;43(1):1329-1337.
- Diebold M, Schaub S, Landmann E, Steiger J, Dickenmann M. Acute kidney injury in patients with COVID-19: a retrospective cohort study from Switzerland. *Swiss Med Wkly*. 2021;151:w20482.
- Costa RLD, Sória TC, Salles EF, Gerech AV, Corvisier MF, Menezes MAM, et al. Acute kidney injury in patients with Covid-19 in a Brazilian ICU: incidence, predictors and in-hospital mortality. *J Bras Nefrol*. 2021;43(3):349-358.
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
- Naser MN, Al-Ghatam R, Darwish AH, Alqahtani MM, Alahmadi HA, Mohamed KA, et al. Risk factors, predictions, and progression of acute kidney injury in hospitalized COVID-19 patients: An observational retrospective cohort study. *PLoS One*. 2021;16(9):e0257253.
- Li XQ, Liu H, Meng Y, Yin HY, Gao WY, Yang X, et al. Critical roles of cytokine storm and secondary bacterial infection in acute kidney injury development in COVID-19: A multi-center retrospective cohort study. *J Med Virol*. 2021;93(12):6641-6652.
- Alfano G, Ferrari A, Fontana F, Mori G, Magistroni R, Meschiari M, et al. Incidence, risk factors and outcome of acute kidney injury (AKI) in patients with COVID-19. *Clin Exp Nephrol*. 2021;25(11):1203-1214.
- Chopra S, Saha A, Kumar V, Thakur A, Pemde H, Kapoor D, et al. Acute Kidney Injury in Hospitalized Children with COVID19. *J Trop Pediatr*. 2021;67(2):037.
- Charoenngam N, Ilori TO, Holick MF, Hochberg NS, Apovian CM. Self-identified Race and COVID-19-Associated Acute Kidney Injury and Inflammation: a Retrospective Cohort Study of Hospitalized Inner-City COVID-19 Patients. *J Gen Intern Med*. 2021;36(11):3487-3496.
- Caceres PS, Savickas G, Murray SL, Umanath K, Uduman J, Yee J, et al. High SARS-CoV-2 Viral Load in Urine Sediment Correlates with Acute Kidney Injury and Poor COVID-19 Outcome. *J Am Soc Nephrol*. 2021;32(10):2517-2528.

Movahed SMM, Akhavizadegan H, Dolatkhani F, Nejadghaderi SA, Aghajani F, Faghir Gangi M, et al. Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: A retrospective study. *J Med Virol*. 2021;93(7):4411-4419.

Lowe R, Ferrari M, Nasim-Mohi M, Jackson A, Beecham R, Veighey K, et al. Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study. *BMC Nephrol*. 2021;22(1):92.

See YP, Young BE, Ang LW, Ooi XY, Chan CP, Looi WL, et al. Risk Factors for Development of Acute Kidney Injury in COVID-19 Patients: A Retrospective Observational Cohort Study. *Nephron*. 2021;145(3):256-264.

Piñeiro GJ, Molina-Andújar A, Hermida E, Blasco M, Quintana LF, Rojas GM, et al. Severe acute kidney injury in critically ill COVID-19 patients. *J Nephrol*. 2021;34(2):285-293.

Wang X, Chen X, Tang F, Luo W, Fang J, Qi C, et al. Be aware of acute kidney injury in critically ill children with COVID-19. *Pediatr Nephrol*. 2021;36(1):163-169.

Yan Q, Zuo P, Cheng L, Li Y, Song K, Chen Y, et al. Acute Kidney Injury Is Associated With In-hospital Mortality in Older Patients With COVID-19. *J Gerontol A Biol Sci Med Sci*. 2021;76(3):456-462.

Li Q, Zhang T, Li F, Mao Z, Kang H, Tao L, et al. Acute Kidney Injury Can Predict In-Hospital Mortality in Elderly Patients with COVID-19 in the ICU: A Single-Center Study. *Clin Interv Aging*. 2020;15:2095-2107.

Trabulus S, Karaca C, Balkan II, Dincer MT, Murt A, Ozcan SG, et al. Kidney function on admission predicts in-hospital mortality in COVID-19. *PLoS One*. 2020;15(9):e0238680.

Oussalah A, Gleye S, Clerc Urmes I, Laugel E, Callet J, Barbé F, et al. Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France. *Clin Infect Dis*. 2020;71(9):2447-2456.

Ozsurekci Y, Oygur PD, Gürlevik SL, Kesici S, Ozen S, Kurt Sukur ED, et al. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe? *Pediatr Nephrol*. 2021;36(11):3771-3776.